Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eluate testing with monospecific antisera unmasks multiple immunoglobulin classes and identifies frequent IgA involvement in severe autoimmune hemolytic anemia.
Bezirgiannidou Z, Kontekaki E, Christoforidou A, Zisaki S, Chouchos K, Papamichos S, Vrachiolias G, Papoutselis M, Spanoudakis E, Martinis G, Kotsianidis I, Mantadakis E. Bezirgiannidou Z, et al. Among authors: kotsianidis i. Transfus Apher Sci. 2018 Jun;57(3):384-387. doi: 10.1016/j.transci.2018.04.020. Epub 2018 Apr 22. Transfus Apher Sci. 2018. PMID: 29716828 No abstract available.
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
Christoforidou A, Pantelidou D, Anastasiadis A, Goutzouvelidis A, Margaritis D, Kotsianidis I, Spanoudakis E, Kaloutsi V, Bourikas G, Tsatalas C. Christoforidou A, et al. Among authors: kotsianidis i. Acta Haematol. 2008;120(4):195-8. doi: 10.1159/000189381. Epub 2009 Jan 8. Acta Haematol. 2008. PMID: 19129692 No abstract available.
Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status.
Vadikolia CM, Tsatalas C, Anagnostopoulos K, Trypsianis G, Pantelidou D, Bazdiara I, Anastasiadis A, Spanoudakis E, Kotsianidis I, Margaritis D, Kortsaris A, Bourikas G. Vadikolia CM, et al. Among authors: kotsianidis i. Acta Haematol. 2011;126(1):54-62. doi: 10.1159/000324436. Epub 2011 Apr 7. Acta Haematol. 2011. PMID: 21474922
Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine.
Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, Kotsianidis I. Miltiades P, et al. Among authors: kotsianidis i. Blood Cancer J. 2014 Feb 28;4(2):e187. doi: 10.1038/bcj.2014.9. Blood Cancer J. 2014. PMID: 24583533 Free PMC article. No abstract available.
149 results